PharmaTimesOriginal article
AC Immune reports positive phase 1 data for ACI‑19764
Phase 1positiveACI-19764Positive
AI Analysis
Summary
AC Immune reported positive Phase 1 data for ACI-19764, demonstrating safety, cerebrospinal fluid penetration, and pharmacokinetic clarity in early clinical evaluation.
Clinical Trial Data
Phase
1
Outcome Details
Early results show safety, CSF penetration and PK clarity
Importance:5/10
Sentiment:
0.70
Phase 1 datasafety profileCNS penetrationpharmacokinetics
Related Companies
Read the original article
Published by PharmaTimes on August 25, 2026 2:08 PM